司奎那定 | 57734-69-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 司奎那定
• 中文别名: 西奎芬定
• 英文名称: (Quinuclidyl-3)-di(o-tolyl)carbinol
• 英文别名: 3-Chinuclidyl-di-(2'-tolyl-carbinol)；(1-aza-bicyclo[2.2.2]oct-3-yl)-di-o-tolyl-methanol；Sequifenadine；1-azabicyclo[2.2.2]octan-3-yl-bis(2-methylphenyl)methanol
• CAS: 57734-69-7
• 化学式: C₂₂H₂₇NO
• 分子量: 321.462
• InChiKey: OXDOWGVJMITMJL-UHFFFAOYSA-N

物化性质

• 熔点：
  238-240 °C
• 沸点：
  455.0±40.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

制备方法与用途

Sequifenadine 是一种 H1 抗组胺药，可能适用于研究伴有过敏症状的眼部炎症疾病。

反应信息

• 作为反应物：
  描述：

  司奎那定 在 双氧水 作用下， 以 甲醇 为溶剂， 反应 5.0h， 生成 alpha,alpha-二(2-甲基苯基)-1-氮杂双环(2.2.2)辛烷-3-甲醇 1-氧化物
  参考文献：
  名称：

  Investigation of the metabolism of the o-tolyl analog of fencarol

  摘要：

  DOI：

  10.1007/bf00770306

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• IMPLANTED DEVICE
  申请人：Lifetech Scientific (Shenzhen) Co., Ltd.

  公开号：EP3400969A1

  公开（公告）日：2018-11-14

  Disclosed is an implantable device, comprising a device base body and an active drug, wherein the device base body is pure zinc and/or a zinc alloy, the zinc content in the device base body is 0.1-100%, and the active drug comprises anti-allergic drugs. After the implantation of the implantable device into the human body, the surrounding tissues of the implant would not have a clear hypersensitive reaction due to the presence of the anti-allergic drugs, and the implanted device can be used to be implanted into the body for supporting organ chambers, to fill the hollow chambers of the organs and tissues or as orthopaedic implants etc.

  本发明公开了一种植入式装置，包括装置基体和活性药物，其中装置基体为纯锌和/或锌合金，装置基体中的锌含量为0.1-100%，活性药物包括抗过敏药物。该植入装置植入人体后，植入体周围组织不会因抗过敏药物的存在而产生明显的过敏反应，该植入装置可用于植入人体支撑器官腔室、填充器官组织中空腔室或作为骨科植入物等。
• ABSORBABLE IRON-BASED ALLOY IMPLANTABLE MEDICAL DEVICE
  申请人：Lifetech Scientific (Shenzhen) Co., Ltd.

  公开号：EP3400971A1

  公开（公告）日：2018-11-14

  An absorbable iron-based alloy implantable medical device, including an iron-based alloy substrate and a degradable polymer coating and a zinc-containing protector which are arranged on the surface of the iron-based alloy substrate. The zinc-containing protector is selected from zinc and/or a zinc alloy, or a mixture of zinc and/or a zinc alloy and a degradable binder. The weight percentage of the zinc and/or zinc alloy in the mixture is greater than or equal to 20% and less than 100%. The zinc-containing protector is capable of delaying the corrosion of the iron-based alloy substrate during the early stage of implantation, such that the iron-based alloy substrate essentially avoids corrosion during the early stage of implantation and the clinical mechanical property requirements for the device in the early stage of implantation can be satisfied.

  一种可吸收的铁基合金植入式医疗器械，包括铁基合金基底、可降解聚合物涂层和含锌保护剂，它们被布置在铁基合金基底的表面上。含锌保护剂选自锌和/或锌合金，或锌和/或锌合金与可降解粘合剂的混合物。混合物中锌和/或锌合金的重量百分比大于或等于 20%，小于 100%。含锌保护剂能够延缓铁基合金基底在植入早期阶段的腐蚀，从而使铁基合金基底在植入早期阶段基本避免腐蚀，并满足植入早期阶段装置的临床机械性能要求。
• ABSORBABLE IRON-BASED ALLOY MEDICAL DEVICE IMPLANT
  申请人：Lifetech Scientific (Shenzhen) Co., Ltd.

  公开号：EP3400970A1

  公开（公告）日：2018-11-14

  An absorbable iron-based alloy medical device implant, comprising an iron-based alloy substrate (11) and a degradable polymer (13) provided on a surface of an iron-based alloy substrate (11), and a zinc-containing protective member (12) provided on the surface of the iron-based alloy substrate (11). The zinc-containing protective member (12) is either a zinc compound or a mixture comprising the zinc compound and at least one of a phosphate-containing compound, a degradable binder, or a water-soluble binder. The weight ratio of the zinc compound in the mixture is ≥ 20% and < 100%. The zinc-containing protective member (12) can delay corrosion of the iron-based alloy substrate (11) during an early stage of medical device implantation. The iron-based alloy substrate (11) is essentially corrosion-free during the early stage of medical device implantation, and is therefore able to satisfy clinical requirements of mechanical performance during the early stage of medical device implantation.

  一种可吸收铁基合金医疗器械植入物，包括铁基合金基板（11）和设置在铁基合金基板（11）表面的可降解聚合物（13），以及设置在铁基合金基板（11）表面的含锌保护件（12）。含锌保护件（12）是锌化合物或由锌化合物和含磷酸盐化合物、可降解粘合剂或水溶性粘合剂中至少一种组成的混合物。混合物中锌化合物的重量比≥ 20% < 100%。在医疗设备植入的早期阶段，含锌保护部件（12）可以延缓铁基合金基底（11）的腐蚀。在医疗器械植入的早期阶段，铁基合金基板（11）基本上不会被腐蚀，因此能够满足医疗器械植入早期阶段对机械性能的临床要求。